Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Dainippon options rights to SanBio's stroke candidate SB623; exercised; terminated

Executive Summary

SanBio Inc. (neural stem cell medicines) has given Dainippon Sumitomo Pharma Co. Ltd., the drug and food products division of Sumitomo Chemical Co., an option to license exclusive US and Canadian development and marketing rights to its lead candidate SB623, which is undergoing preclinical tests for disabilities caused by stroke.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies